MTOR and ovarian hyperstimulation syndrome: In vivo studies have also suggested that mTOR inhibitors may prevent ovarian hyperstimulation syndrome (OHSS) by controlling immune responses and VEGF-mediated angiogenesis (Kosmas et al., 2015; Kitsou et al., 2016; Liu et al., 2019a).